LadRx Corporation today announced that its previously announced reverse stock split of its common stock at a ratio of 1 post-split share for every 100 pre-split shares became effective at 5:00 a.m. PDT on Wednesday, May 17, 2023.
LadRx Announces Reverse Stock Split Effective as of May 17, 2023 Read More »
FDA Approves Next Generation MicroPort CRM Alizea TM and Celea TM Pacemaker Systems.
FDA Approves Next Generation MicroPort CRM AlizeaTM and CeleaTM Pacemaker Systems Read More »
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today reported its first quarter 2023 unaudited financial results.
Legend Biotech Reports First Quarter 2023 Results and Recent Highlights Read More »
HeartBeam, Inc. today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for its HeartBeam AIMIGo™ System.
HeartBeam Announces FDA Submission of HeartBeam AIMIGo™ VECG System Read More »
Teva Pharmaceutical Industries Ltd. today announced a new strategic framework with four main pillars to position the Company for a new era of growth.
NanoVibronix, Inc. today issued a letter to shareholders from its Chief Executive Officer, Brian Murphy, providing a review of the first quarter 2023 and recent business developments.
NanoVibronix Issues Letter to Shareholders – May 18, 2023 Read More »
Noticias de la actualidad científica y tecnológica del 15 de mayo de 2023. …
CARsgen Therapeutics Holdings Limited announced that CARsgen has initiated patient enrollment for Phase 2 of the clinical trial for CT041 in the U.S., for the treatment of CLDN18.2 positive advanced gastric cancer/gastroesophageal junction cancer (GC/GEJ) in patients who have failed at least 2 prior lines of systemic therapies.
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that Hepatology Communications published data from the CAMEO study evaluating the safety, tolerability, and efficacy of LIVMARLI® (maralixibat) oral solution in patients with primary sclerosing cholangitis (PSC).
Protalix BioTherapeutics, Inc. today announced that it is eligible to receive a $20 million milestone payment from its commercial partner, Chiesi Global Rare Diseases, a business unit of the Chiesi Group.
